Treatment of cancers with A-8R peptide
Patent Number: US8575087
Executive Summary:
General Description:
The present invention is based, at least in part, on the discovery that the protein product of this new gene is able to down-regulate p53 activity in prostate cancer cells. Since disrupting mutations of p53 mainly occur in late-stage, hormone-refractory prostate tumors and are found in less than 50% of these tumors, the inventor's new mechanism of p53 down-regulation is now believed to be important in those 50% of tumors that express wild-type p53 protein. It is also now believed that disrupting this mechanism of p53 down-regulation may provide a new therapy against such tumors.
Strengths:
Weaknesses:
Patent Status:
Inventor Bio: Lirim Shemshedini
http://www.utoledo.edu/nsm/bio/research/shemshedini.html
Executive Summary:
- Invention Type: Diagnostic/Therapeutic
- Patent Status: Active
- Patent Link: https://patents.google.com/patent/US8575087/
- Research Institute: University of Toledo
- Disease Focus: Prostate cancer
- Basis of Invention: The importance of the androgen receptor in the development of prostate cancer is demonstrated by the success of anti-androgen therapy at the early stages of prostate cancer. Hormone ablation therapies continue to dominate the market, as they have proven to be the most effective at treating the early stage prostate cancer, which is hormone-dependent. However, this therapy and others currently used are ineffective against late-stage prostate cancer, which is hormone-refractory and usually lethal
- How it works: Peptides which interfere with sGCα1's pro-survival functions, thereby resulting in apoptosis of sGCα1-expressing cells
- Lead Challenge Inventor: Lirim Shemshedini
- Inventors: Lirim Shemshedini, Shao-Yong Chen, Changmeng Cai, Chen-Lin Hsieh
- Development Stage: Pre-clinical, Validation of the lead peptide in xenograft mouse model
- Novelty:
- Method to treat and diagnose sGCα1-expressing cancers using peptides that interfere with sGCa1 pro-survival properties and down-regulate p53
- This may also serve as a biomarker for treatable cancers
- Clinical Applications:
- Inhibitor is capable of reducing sGCa1-associated p53 inhibition
General Description:
The present invention is based, at least in part, on the discovery that the protein product of this new gene is able to down-regulate p53 activity in prostate cancer cells. Since disrupting mutations of p53 mainly occur in late-stage, hormone-refractory prostate tumors and are found in less than 50% of these tumors, the inventor's new mechanism of p53 down-regulation is now believed to be important in those 50% of tumors that express wild-type p53 protein. It is also now believed that disrupting this mechanism of p53 down-regulation may provide a new therapy against such tumors.
Strengths:
- Preclinical data looks convincing and has many implications in therapeutic and diagnostic areas. Peptides are easily made and delivered, increasing the efficacy of this as a therapeutic.
Weaknesses:
- Hormone therapy already in use
Patent Status:
- Filing date – 2010-05-28
- Publication date – 2013-11-05
- Grant date – 2013-11-05
Inventor Bio: Lirim Shemshedini
http://www.utoledo.edu/nsm/bio/research/shemshedini.html
